Boston Scientific Cleared For Next-Gen Deep Vein Thrombosis Catheter
This article was originally published in The Gray Sheet
A year after Boston Sci bought Bayer's interventional unit, Medrad, the company says it has received a 510(k) clearance for its ZelanteDVT catheter to be used with its AngioJet Ultra Console to treat deep vein thrombosis as mechanical – rather than drug – DVT treatments are gaining more attention.
You may also be interested in...
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
The European Safety Authority is running consultations on its proposals to set safe intake levels from foods, including dietary supplements, for iron and vitamin A.
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.